[{"id":"99825282-13d0-4537-9611-5aeeb9d9b074","acronym":"PCEDP","url":"https://clinicaltrials.gov/study/NCT02206360","created_at":"2021-01-18T10:19:50.126Z","updated_at":"2024-07-02T16:35:01.200Z","phase":"","brief_title":"Pancreatic Cancer Early Detection Program","source_id_and_acronym":"NCT02206360 - PCEDP","lead_sponsor":"White Plains Hospital","biomarkers":" BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":" | ","alterations":" TP53 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-05-24"},{"id":"46d378ac-a32a-49b5-8f63-3c539b277a13","acronym":"QPCS","url":"https://clinicaltrials.gov/study/NCT04104230","created_at":"2021-01-18T20:04:23.369Z","updated_at":"2024-07-02T16:35:09.050Z","phase":"","brief_title":"Quebec Pancreas Cancer Study","source_id_and_acronym":"NCT04104230 - QPCS","lead_sponsor":"George Zogopoulos","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":" | ","alterations":" ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 03/12/2012","start_date":" 03/12/2012","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-04-17"},{"id":"107dd190-b738-4816-b39c-d6828e427b79","acronym":"PancreasScan","url":"https://clinicaltrials.gov/study/NCT05006131","created_at":"2021-08-16T17:54:43.106Z","updated_at":"2024-07-02T16:35:13.981Z","phase":"","brief_title":"Pancreatic Cancer Screening for At-risk Individuals","source_id_and_acronym":"NCT05006131 - PancreasScan","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • BRCA • EPCAM • PRSS1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS2 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • BRCA • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS2 mutation • BRCA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 07/10/2020","start_date":" 07/10/2020","primary_txt":" Primary completion: 03/10/2027","primary_completion_date":" 03/10/2027","study_txt":" Completion: 03/10/2028","study_completion_date":" 03/10/2028","last_update_posted":"2024-03-19"},{"id":"66853300-b253-4b97-9f2f-41f422c3a06a","acronym":"CAPS5","url":"https://clinicaltrials.gov/study/NCT02000089","created_at":"2021-01-18T09:07:46.938Z","updated_at":"2024-07-02T16:35:14.360Z","phase":"Phase 3","brief_title":"The Cancer of the Pancreas Screening-5 CAPS5)Study","source_id_and_acronym":"NCT02000089 - CAPS5","lead_sponsor":"Johns Hopkins University","biomarkers":" BRCA1 • BRCA2 • MSH2 • PRSS1 • CA 19-9 • CTRC","pipe":" | ","alterations":" BRCA1 mutation • PALB2 mutation","tags":["BRCA1 • BRCA2 • MSH2 • PRSS1 • CA 19-9 • CTRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • PALB2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 7000","initiation":"Initiation: 01/06/2014","start_date":" 01/06/2014","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-18"},{"id":"942c232f-7333-4f3f-b161-29ff99678077","acronym":"","url":"https://clinicaltrials.gov/study/NCT06122896","created_at":"2023-11-08T22:13:14.798Z","updated_at":"2024-07-02T16:35:17.268Z","phase":"Phase 1","brief_title":"Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals","source_id_and_acronym":"NCT06122896","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TP53 • BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":"","alterations":" ","tags":["TP53 • BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 11/21/2023","start_date":" 11/21/2023","primary_txt":" Primary completion: 10/31/2040","primary_completion_date":" 10/31/2040","study_txt":" Completion: 10/31/2041","study_completion_date":" 10/31/2041","last_update_posted":"2024-02-28"},{"id":"ccac9502-7e33-40ca-9264-1fc18521851a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02070705","created_at":"2021-01-18T09:32:25.096Z","updated_at":"2024-07-02T16:35:18.278Z","phase":"","brief_title":"DCE MRI in Patients With Pancreatic Cancer","source_id_and_acronym":"NCT02070705","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" BRCA1 • BRCA2 • STK11 • MSH6 • BRCA • PRSS1","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • STK11 • MSH6 • BRCA • PRSS1"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/31/2014","start_date":" 01/31/2014","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-21"},{"id":"cb6e094e-2742-489c-80fc-e3915d2584c6","acronym":"PREPAIRD","url":"https://clinicaltrials.gov/study/NCT05740111","created_at":"2023-02-22T15:01:18.890Z","updated_at":"2024-07-02T16:35:54.968Z","phase":"","brief_title":"The PREPAIRD Study: Personalized Surveillance for Early Detection of Pancreatic Cancer in High Risk Individuals","source_id_and_acronym":"NCT05740111 - PREPAIRD","lead_sponsor":"Oslo University Hospital","biomarkers":" TP53 • STK11 • CDKN2A • PRSS1","pipe":" | ","alterations":" TP53 mutation • STK11 mutation • CDKN2A mutation","tags":["TP53 • STK11 • CDKN2A • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • STK11 mutation • CDKN2A mutation"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 200","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 12/31/2042","primary_completion_date":" 12/31/2042","study_txt":" Completion: 12/31/2042","study_completion_date":" 12/31/2042","last_update_posted":"2023-02-22"},{"id":"95b1b72a-6b16-418e-8e37-09f5e641a8f8","acronym":"IRFARPC","url":"https://clinicaltrials.gov/study/NCT04095195","created_at":"2021-01-18T20:02:14.758Z","updated_at":"2024-07-02T16:35:57.607Z","phase":"","brief_title":"Registry of Subjects at Risk of Pancreatic Cancer","source_id_and_acronym":"NCT04095195 - IRFARPC","lead_sponsor":"Associazione Italiana per lo Studio del Pancreas","biomarkers":" BRCA1 • BRCA2 • BRCA • PRSS1","pipe":" | ","alterations":" BRCA1 mutation • PALB2 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • PALB2 mutation • BRCA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 08/20/2019","start_date":" 08/20/2019","primary_txt":" Primary completion: 08/20/2044","primary_completion_date":" 08/20/2044","study_txt":" Completion: 09/20/2045","study_completion_date":" 09/20/2045","last_update_posted":"2023-01-13"},{"id":"053f27e7-25b9-4207-ab75-19a39c4c5d38","acronym":"","url":"https://clinicaltrials.gov/study/NCT03693378","created_at":"2021-01-18T18:06:04.652Z","updated_at":"2024-07-02T16:36:14.357Z","phase":"","brief_title":"A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups","source_id_and_acronym":"NCT03693378","lead_sponsor":"Immunovia, Inc.","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":" | ","alterations":" ATM mutation • STK11 mutation • PALB2 mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • STK11 mutation • PALB2 mutation"],"overall_status":"Completed","enrollment":" Enrollment 1349","initiation":"Initiation: 01/19/2016","start_date":" 01/19/2016","primary_txt":" Primary completion: 11/12/2021","primary_completion_date":" 11/12/2021","study_txt":" Completion: 11/12/2021","study_completion_date":" 11/12/2021","last_update_posted":"2022-03-31"},{"id":"974fb86f-1c97-45d1-a1f2-188f45e1a936","acronym":"","url":"https://clinicaltrials.gov/study/NCT02309632","created_at":"2021-01-18T10:54:21.558Z","updated_at":"2024-07-02T16:36:57.624Z","phase":"","brief_title":"Pancreatic Cancer Screening of High-Risk Individuals in Arkansas","source_id_and_acronym":"NCT02309632","lead_sponsor":"University of Arkansas","biomarkers":" BRCA1 • BRCA2 • STK11 • MSH2 • BRCA • PRSS1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • PALB2 mutation","tags":["BRCA1 • BRCA2 • STK11 • MSH2 • BRCA • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • PALB2 mutation"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 07/19/2019","primary_completion_date":" 07/19/2019","study_txt":" Completion: 07/19/2019","study_completion_date":" 07/19/2019","last_update_posted":"2019-07-29"}]